2023 World Conference on Lung Cancer (Posters)-P1.06. NIR-II Mediates Non-small Cell Lung Cancer Nanovaccines for Targeted Lymph Node Delivery and Anti-tumor Immune Activation

P1.06. NIR-II Mediates Non-small Cell Lung Cancer Nanovaccines for Targeted Lymph Node Delivery and Anti-tumor Immune Activation - PDF(Abstract)

Back to course

Pdf Summary

Researchers have developed a new strategy for enhancing the immune response in non-small cell lung cancer (NSCLC) immunotherapy using nanovaccines. The study aims to address the low immune response rate observed in NSCLC immunotherapy by delivering personalized cancer nanovaccines to lymph nodes. The researchers used gold nanorods modified with PEG and loaded with an immune adjuvant called R848, as well as cationic liposome DOTAP nanoparticles, to create the nanovaccines. The gold nanorods were found to have a good photothermal effect, producing a large number of antigens under NIR-II. The PEG-modified gold nanorods were able to capture the antigens generated and deliver them to lymph nodes to initiate an effective anticancer immune response. When combined with an anti-CTLA4 antibody, the nanovaccine therapy completely eradicated distant tumors in some mice and produced a long-term immune memory effect on NSCLC metastasis. This study provides a promising approach to enhance the antitumor immunity of cancer vaccines and could be used in personalized vaccination for cancer therapy.

Asset Subtitle

Haiyu Zhou

Meta Tag

Speaker Haiyu Zhou

Topic Tumor Biology: Preclinical Biology - Tumor Immunity

Keywords

immune response

non-small cell lung cancer

NSCLC

immunotherapy

nanovaccines

lymph nodes

gold nanorods

PEG

R848

cationic liposome DOTAP nanoparticles